Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Interview · June 27, 2021

Nivolumab/Ipilimumab With Gut Microbiome Modulation for Patients With mRCC

Jun Gong MD
Interview by
Jun Gong MD
Sumanta Pal MD
Interview with
Sumanta Kumar Pal MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Jun Gong MD

Sumanta Pal MD

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading

Related Videos